Neuropsychopharmacology
- Spotlighting SHAPERS: sex hormones associated with psychological and endocrine roles2 years ago
- Reply to Sun: Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection2 years ago
- Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection2 years ago
- Social isolation and aggression training lead to escalated aggression and hypothalamus-pituitary-gonad axis hyperfunction in mice2 years ago
- tRNA epitranscriptomic alterations associated with opioid-induced reward-seeking and long-term opioid withdrawal in male mice2 years ago
- White and gray matter alterations in bipolar I and bipolar II disorder subtypes compared with healthy controls – exploring associations with disease course and polygenic risk2 years ago
- Two polygenic mouse models of major depressive disorders identify TMEM161B as a potential biomarker of disease in humans2 years ago
Journal of Psychopharmacology
- To BDZ or not to BDZ? That is the question! Is there reliable scientific evidence for or against using benzodiazepines in the aftermath of potentially traumatic events for the prevention of PTSD? A systematic review and meta-analysis4 years ago
- Do antipsychotic drugs shrink the brain? Probably not4 years ago
- The effect of first- and second-generation antipsychotics on brain morphology in schizophrenia: A systematic review of longitudinal magnetic resonance studies with a randomized allocation to treatment arms4 years ago
- Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms4 years ago
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension4 years ago
- Clozapine and the aryl hydrocarbon receptor4 years ago
- The effect of metformin on cognitive function: A systematic review and meta-analysis4 years ago
European Neuropsychopharmacology
- Erratum to “Digital tools for the assessment of pharmacological treatment for depressive disorder: State of the Art. [European Neuropsychopharmacology 60 (2022) 100–116]”3 years ago
- Comment to “Requiem or resurrection: Classic monoamine oxidase inhibitors revisited”3 years ago
- A polygenic-informed approach to a predictive EEG signature empowers antidepressant treatment prediction: A proof-of-concept study3 years ago
- Associations between oxidative stress markers and patient-reported smartphone-based symptoms in patients newly diagnosed with bipolar disorder: An exploratory study3 years ago
- The future of antipsychotics studies: How innovative designs may benefit patients with psychotic disorders3 years ago
- New antidepressants: New day or false dawn?3 years ago
- Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism3 years ago